GLIOMA INTERACTION WITH THE NEUROGENIC NICHE THROUGH EXTRACELLULAR VESICLES

NIH RePORTER · NIH · R21 · $430,375 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT Glioblastoma (GBM) is the most common, aggressive and proliferative primary brain tumor in adults despite current therapeutic strategies that combine surgery, radiation, and chemotherapy. The high invasive capacity of GBM makes total surgical resection virtually impossible, resulting in an extremely high recurrence rate. The ability to form a new tumor resides in a subpopulation of cells within the GBM called brain tumor initiating cells (BTICs). BTICs are undifferentiated cells with self-renewing and pluripotential capacity, similar to neural stem cells (NSCs), but with the added ability of forming tumors in vivo. Our group and others have reported that among primary GBMs, those that are located in close proximity to the lateral ventricles (LV) present multiple factors, including increased recurrence at distant locations, that negatively affect patients’ survival. Possible explanations may involve the proximity of these tumors to the cerebrospinal fluid (CSF) and neurogenic niche in the subventricular zone (SVZ). We have previously reported that GBM tumors infiltrating the LV disrupt SVZ homeostasis, inducing signs of senescence in NPC and allowing CSF infiltration. The ensuing interaction with CSF heightens the proliferation and migration capacity of GBM-BTICs, fostering a more aggressive phenotype. However, the mechanisms used by GBM cells to modify the SVZ niche and the LV wall are not understood. In our preliminary studies we have observed extracellular vesicles (EVs) play an important role in the intercellular communication between BTICs and NPCs. The proposal's primary objective is to explore the role of EVs in mediating communication between GBM cells and the tumor microenvironment, specifically within the SVZ. Additionally, the research aims to evaluate EVs as potential biomarkers for monitoring brain tumor response to treatment and predicting recurrence.

Key facts

NIH application ID
10999368
Project number
1R21NS128212-01A1
Recipient
MAYO CLINIC JACKSONVILLE
Principal Investigator
Hugo Guerrero-Cazares
Activity code
R21
Funding institute
NIH
Fiscal year
2024
Award amount
$430,375
Award type
1
Project period
2024-09-01 → 2026-08-31